GUTS

Fractyl Health Inc

0.8812

Nov 11 • 3:59 PM ET +0.0705 (8.70%)

0.8589

Aftermarket • 6:03 PM ET -0.0223 (-2.53%)

Healthcare Biotechnology USA Nano NASD

Peers: BMEA AARD ALT SKYE GPCR MBX VKTX LXRX RYTM BIOA

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	11.68M
Enterprise Value	25.28M
Income	-105.65M
Sales	0.00M
Book/sh	-0.13
Cash/sh	3.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	100
IPO	Feb 02, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	0.25
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.15
Current Ratio	3.15
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-13.12
EPS next Y	-5.79
EPS next Q	-1.50
EPS this Y	81.17%
EPS next Y	-37.72%
EPS next 5Y	42.51%
EPS past 3/5Y	-11.62% -16.69%
Sales past 3/5Y	- -
EPS Y/Y TTM	46.66%
Sales Y/Y TTM	-100.00%
EPS Q/Q	71.69%
Sales Q/Q	-
Earnings	Nov 12 AMC
EPS/Sales Surpr.	-18.52% -

Insider Own	15.01%
Insider Trans	13.45%
Inst Own	38.06%
Inst Trans	-3.37%
ROA	-146.75%
ROE	-778.33%
ROIC	-196.04%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-26.00%
SMA50	-78.99%
SMA200	-87.31%
Trades

Shs Outstand	13.22M
Shs Float	11.27M
Short Float	5.19%
Short Ratio	1.24
Short Interest	0.59M
52W High	29.34 -97.00%
52W Low	0.81 8.76%
Volatility	10.96% 13.96%
ATR (14)	0.26
RSI (14)	20.86
Beta	2.91
Rel Volume	0.30
Avg Volume	472.38K
Volume	141,098

Perf Week	-9.39%
Perf Month	-78.11%
Perf Quarter	-88.91%
Perf Half Y	-92.26%
Perf YTD	-96.66%
Perf Year	-93.32%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	41.20
Prev Close	0.81
Price	0.88
Change %	8.70%

Consensus

Strong Buy

Avg. Price Target

$41.20

Implied Upside

+4,575.4%

Analysts5incl. previous ratings

Rating Distribution4 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 30, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$2	+127.0%
Sep 15, 2025	Initiated	HH.C. Wainwright	Buy	$9	+921.3%
Aug 28, 2025	Initiated	LLadenburg Thalmann	Buy	$3.60	+308.5%
Feb 28, 2024	Initiated	EEvercore ISI	Outperform
Feb 27, 2024	Initiated	MMorgan Stanley	Overweight	$18	+1,942.7%
Feb 27, 2024	Initiated	BBofA Securities	Buy	$26	+2,850.5%

Nov-07-26 08:42AM	Fractyl Health's Q3 Report Becomes A Test Of Cash And Credibility After An 88% Collapse (Earnings Whispers)
Nov-06-26 07:00AM	Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026 (GlobeNewswire)
Oct-30-26 07:00AM	Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization (GlobeNewswire)
Oct-29-26 07:00AM	Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance (GlobeNewswire) +11.40%
Oct-22-26 07:00AM	Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance (GlobeNewswire)
09:32AM	Loading…
Oct-16-26 09:32AM	Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans (InvestorsHub) -62.74%
07:00AM	Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation (GlobeNewswire)
Sep-29-26 08:56PM	Robbins LLP is Investigating Allegations that Fractyl Health, Inc. Misled Investors Regarding the Viability and Efficacy of its Revita DMR System (Newsfile) +10.40%
Sep-16-26 07:33PM	GUTS Stockholders Have Rights - If you Lost Money Investing in Fractyl Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire) +5.03%
Sep-09-26 07:00AM	Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire) -6.60%
Sep-03-26 10:40AM	Did You Lose Money Investing in Fractyl Health, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against GUTS (Newsfile)
Sep-01-26 08:56AM	Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day (InvestorsHub)
Aug-20-26 07:00AM	Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita, a Procedural Therapy for Post-GLP-1 Weight Maintenance (GlobeNewswire)
Aug-11-26 01:03AM	Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ... (GuruFocus.com)
Aug-10-26 04:05PM	Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
04:05PM	Loading…
Aug-03-26 04:05PM	Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026 (GlobeNewswire)
Jul-22-26 04:01PM	Fractyl Health to Participate in Upcoming Investor Events (GlobeNewswire)
Jul-15-26 06:00AM	Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation (GlobeNewswire) +13.75%
Jun-04-26 07:00AM	Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure (GlobeNewswire)
Jun-01-26 07:00AM	Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy (GlobeNewswire) +7.57%
May-13-26 01:02AM	Fractyl Health Inc (GUTS) Q1 2026 Earnings Call Highlights: Pivotal Trial Progress and ... (GuruFocus.com) +29.20%
May-12-26 04:05PM	Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
May-11-26 07:00AM	Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes (GlobeNewswire)
06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive)
May-05-26 07:00AM	Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference (GlobeNewswire)
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire) -5.20%
Mar-24-26 11:01PM	Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) +16.17%
04:01PM	Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire)
Mar-17-26 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 (GlobeNewswire)
Feb-26-26 07:00AM	Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance (GlobeNewswire) -6.19%
09:35AM	Loading…
Feb-23-26 09:35AM	Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-29-26 01:48PM	Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product (Benzinga) -68.04%
12:12PM	Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain (MarketBeat)
07:00AM	Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation (GlobeNewswire)
Jan-06-26 07:00AM	Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness (GlobeNewswire)
Jan-05-26 07:00AM	Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category (GlobeNewswire) -8.44%
Jan-03-26 06:19AM	Analysts Keep Buy Ratings on Fractyl Health (GUTS) (Insider Monkey)
Dec-31-25 11:12AM	Fractyl Health's REVEAL-1 Study Shows Positive Six-Month Results for Revita in Maintaining Weight and Glycemic Control Post-GLP-1 Use (Insider Monkey)
Dec-15-25 05:45PM	Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones (GlobeNewswire)
Dec-02-25 07:00AM	Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure (GlobeNewswire) +17.95%
Dec-01-25 07:00AM	Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-13-25 12:01AM	Fractyl Health Inc (GUTS) Q3 2025 Earnings Call Highlights: Pioneering Weight Loss Solutions ... (GuruFocus.com)
Nov-12-25 04:05PM	Fractyl Health Reports Third Quarter 2025 Results; Revita Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 (GlobeNewswire)
Nov-05-25 07:00AM	Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 (GlobeNewswire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-17-25 09:59AM	Fractyl Health Unveils Potent Preclinical Data for Dual GIP/GLP-1 Gene Therapy RJVA-002 for Obesity (Insider Monkey)
Oct-07-25 07:00AM	Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity (GlobeNewswire) -6.80%
Sep-26-25 07:05AM	Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock (GlobeNewswire) +32.67%
07:00AM	Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation (GlobeNewswire)
Sep-03-25 07:00AM	Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth (GlobeNewswire)
Aug-13-25 03:12AM	Fractyl Health Inc (GUTS) Q2 2025 Earnings Call Highlights: Financial Discipline and Promising ... (GuruFocus.com)
Aug-12-25 04:05PM	Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-07-25 04:05PM	Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-06-25 04:05PM	Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -45.99%
08:30AM	Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering (GlobeNewswire)
Aug-05-25 04:15PM	Fractyl Health Announces Proposed Public Offering (GlobeNewswire)
04:02PM	Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure (GlobeNewswire)
Jul-29-25 10:23AM	Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS) (Insider Monkey) -7.61%
Jun-23-25 07:40AM	Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy (GlobeNewswire) -24.77%
07:30AM	Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models (GlobeNewswire)
Jun-18-25 07:00AM	Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing (GlobeNewswire)
Jun-13-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.07%
07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire)
Jun-04-25 07:00AM	Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide (GlobeNewswire)
May-19-25 07:00AM	Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes (GlobeNewswire) +25.44%
May-17-25 07:15AM	Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 (GlobeNewswire)
May-13-25 04:05PM	Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -13.28%
May-06-25 07:00AM	Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -7.98%
Apr-28-25 04:30PM	Fractyl Health to Present Compelling Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire) +5.00%
Apr-02-25 03:34PM	Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025 (Insider Monkey)
Apr-01-25 07:00AM	Fractyl Health Reports Positive Early Data Showing Revita Has Potential to Prevent Weight Regain After GLP-1 Discontinuation (GlobeNewswire) -6.72%
Mar-03-25 04:05PM	Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Feb-24-25 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 (GlobeNewswire)
Feb-12-25 09:35AM	After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS) (Zacks)
Feb-10-25 03:00AM	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments (Pharma Voice)
Jan-31-25 08:01AM	Fractyl Health Announces Increased Focus on Groundbreaking Revita Weight Maintenance and Rejuva Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 (GlobeNewswire) -5.15%
Jan-13-25 07:00AM	Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort (GlobeNewswire) +5.41%
Jan-06-25 09:10AM	Heres Why Fractyl Health, Inc. (NASDAQ:GUTS) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) -6.36%
Dec-12-24 07:00AM	Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-09-24 07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Nov-26-24 07:00AM	Fractyl Health to Participate in the Upcoming December Conferences (GlobeNewswire)
Nov-12-24 04:05PM	Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-24 04:05PM	Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek 2024 (GlobeNewswire) -9.86% -6.25%
07:00AM	Fractyl Health Presented New Analysis from Pooled Data of Revita Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek 2024 (GlobeNewswire)
Oct-29-24 07:00AM	Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 (GlobeNewswire) +23.19%
Oct-28-24 07:00AM	Fractyl Health to Present Compelling Weight Maintenance Data from both Revita and Rejuva Platforms at ObesityWeek 2024 (GlobeNewswire) +16.46%
Sep-24-24 07:00AM	Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-03-24 07:00AM	Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.38%
Aug-12-24 10:53AM	Rising diabetes rates spur growth in weight management solutions (Medical Device Network) +14.61%
Aug-08-24 12:13PM	Fractyl Health touts positive year-long weight loss results for Revita device (Clinical Trials Arena) -6.19%
08:00AM	Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure (GlobeNewswire)
Aug-07-24 07:00AM	Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 (GlobeNewswire) -9.77%
Jul-30-24 07:00AM	Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs (GlobeNewswire)
Jun-25-24 09:02AM	FDA expands Fractyl endoscopy trial to include untreated diabetes patients (Medical Device Network) -9.22%
07:00AM	Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day (GlobeNewswire)
Jun-24-24 06:00AM	Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates (GlobeNewswire) +5.76%
Jun-23-24 01:30PM	Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-29-24 07:00AM	Fractyl Health to Present New Preclinical Obesity Data from Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-20-24 06:00AM	Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BRADLEY WILLIAM	Director	Sep 14 '26	Buy	0.62	64,516	39,903	149,138	Sep 16 04:05 PM
Royan Ajay	Director	Jun 12 '26	Buy	0.85	23,000	19,596	40,901	Jun 15 06:06 PM
BRADLEY WILLIAM	Director	Jun 10 '26	Buy	0.73	68,493	50,329	84,622	Jun 11 05:04 PM
Sheffield Ian	Director	Jun 10 '26	Buy	0.73	35,000	25,529	35,000	Jun 11 05:00 PM
Rajagopalan Harith	Chief Executive Officer	Jun 10 '26	Buy	0.73	25,000	18,252	540,557	Jun 11 04:59 PM
Smith Weber Lara	Chief Financial Officer	Jun 08 '26	Buy	0.69	20,000	13,708	20,000	Jun 09 06:55 PM
Rajagopalan Harith	Chief Executive Officer	Dec 04 '25	Buy	1.92	10,416	19,999	501,745	Dec 08 07:05 AM

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Ph.D.Dr. Harith Rajagopalan M.D.

General Counsel & Corporate SecretaryMs. Sarah S. Toomey Esq.

CFO & TreasurerMs. Lara Smith Weber

Head of Investor Relations & Corporate DevelopmentMr. Brian Luque

Senior Vice President of RegulatoryMr. Jon Fitzgerald

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

GUTS

Fractyl Health Inc

Upgrade your Finviz experience

All the Features.
Half the Price.